Global Chronic Lymphocytic Leukemia (CLL) Market Size Report For 2015 By Radiant Insights, Inc

Chronic Lymphocytic Leukemia (CLL) Industry Share and Size, Trends and Growth, Analysis and Pipeline Review, H2 2015

Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2015


Global Markets Direct’s, ‘Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2015′, provides an overview of the Chronic Lymphocytic Leukemia (CLL)’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

View Summary of this report @

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

– The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)
– The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in the therapeutics development for Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
– The report summarizes all the dormant and discontinued pipeline projects
– A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– A detailed assessment of monotherapy and combination therapy pipeline projects
– Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
– Latest news and deals relating related to pipeline products

Reasons to Buy
– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Develop strategic initiatives by understanding the focus areas of leading companies
– Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)
– Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
– Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Buy a Sample copy of This Report @

Table Of Contents
Table Of Contents 2
Introduction 7
Chronic Lymphocytic Leukemia (CLL) Overview 8
Therapeutics Development 9
Chronic Lymphocytic Leukemia (CLL) – Therapeutics under Development by Companies 11
Chronic Lymphocytic Leukemia (CLL) – Therapeutics under Investigation by Universities/Institutes 19
Chronic Lymphocytic Leukemia (CLL) – Pipeline Products Glance 21
Chronic Lymphocytic Leukemia (CLL) – Products under Development by Companies 25
Chronic Lymphocytic Leukemia (CLL) – Products under Investigation by Universities/Institutes 38
Chronic Lymphocytic Leukemia (CLL) – Companies Involved in Therapeutics Development 40
Chronic Lymphocytic Leukemia (CLL) – Therapeutics Assessment 132
Drug Profiles 152
Chronic Lymphocytic Leukemia (CLL) – Recent Pipeline Updates 456
Chronic Lymphocytic Leukemia (CLL) – Dormant Projects 656
Chronic Lymphocytic Leukemia (CLL) – Discontinued Products 666
Chronic Lymphocytic Leukemia (CLL) – Product Development Milestones 669
Appendix 681

View Summary of this report @

About Us:

Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details:

Michelle Thoras
Corporate Sales Specialist, USA

Radiant Insights, Inc
28 2nd Street,
Suite 3036 San Francisco,
CA 94105 United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519